TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer
11 Mar 2024
Phase 2Clinical ResultImmunotherapyAACRIND
TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab
TU2218 demonstrated a favorable safety and a synergetic effect with immuno-oncology drugs in preclinical studies
BOSTON and SEONGNAM, South Korea, March 11, 2024 /PRNewswire/ -- TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced that it has submitted Investigational New Drug (IND) application to the Korean Ministry of Food and Drug Safe (MFDS) for a Phase 2a study of TU2218, an oral immuno-oncology drug, in late February, 2024 and that preclinical results of TU2218 will be presented at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting.
TU2218 is a novel oral dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2). TGF-ß and VEGF pathways are known to be factors that interfere with the activity of immuno-oncology drugs, so TU2218 is expected to maximize the efficacy of immuno-oncology drugs by blocking them. TiumBio is currently conducting a Phase 1b clinical trial of TU2218 in combination with Keytruda (pembrolizumab) in advanced solid tumors in the U.S.
For the Phase 2a trial, TiumBio has selected indications in biliary tract cancer (BTC), head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC). The study will enroll up to 116 evaluable participants across three cohorts (up to 40 participants for BTC, up to 36 participants for HNSCC, and up to 40 participants for CRC, respectively) and will evaluate the efficacy and safety of TU2218 administered in combination with pembrolizumab.
Meanwhile, to test the feasibility of various combination options with TU2218, TiumBio conducted in vivo efficacy studies in 4T1, MC39, and CT26 syngeneic tumor models. Results will be presented at the 2024 AACR, taking place from April 5-10 in San Diego, California.
The poster abstract highlights the improved efficacy and safety profile of TU2218 in combination with various immuno-oncology drugs. Specifically, the combination of lenvatinib, anti-PD-1 antibody, and TU2218 demonstrated a significant tumor growth inhibition (TGI) of 99% and a complete response (CR) rate of 67% in the CT 26 model, compared to a TGI of 76% and CR of 17% in the control group receiving only lenvatinib and anti-PD-1 antibody. The statistical difference in anti-tumor activity between the two groups was deemed significant (pwww.tiumbio.com/en and connect with us on LinkedIn.
Contacts:
Junseok Jang, Sr. Manager, Corporate Communications & Investor Relations
[email protected]
Suna Cho, Manager, Corporate Communications & Investor Relations
[email protected]
SOURCE TiumBio
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.